?Bioinformatics and Biotechnology Shared Resource The goal of the Bioinformatics and Biotechnology Shared Resource (BBSR) is to provide the latest innovative, high-throughput biotechnology and bioinformatics methods and approaches to support the cancer research of SJCCC members. The Bioinformatics team provides expert data analysis by utilizing a SJCCC genomic-analysis infrastructure developed and validated through the Pediatric Cancer Genome Project. The Biotechnology team provides state-of-the-art high-throughput genomic assays of RNA and DNA samples by using 3 complementary platforms: genome sequencing, Sanger sequencing, and microarray analysis. The BBSR is directed by Dr. Jinghui Zhang (CBP), Chair of the Department of Computational Biology, who has more than 20 years of research experience in genetic variant characterization in the human genome. She is recognized worldwide for her expertise in the development of novel algorithms, data visualizations, and analyses for deciphering sequence- variation data in pediatric cancer. She is assisted by Dr. Geoffrey Neale, who is responsible for management and scientific oversight of the biotechnology laboratories. He has more than 25 years of experience in scientific management and the investigation of pediatric cancer using molecular techniques. The BBSR is further staffed by a group of PhD-level expert scientists with varied specialization and domain knowledge to support SJCCC projects. Services include technical and analytical support for state-of-the-art molecular profiling, such as next- generation sequencing, microarrays, single-cell sequencing, and CRISPR screening, as well as expert consultation and advisory support. The impact of the BBSR on SJCCC research is evidenced by the significant contribution to publications, many in high-impact journals such as the New England Journal of Medicine, Nature, Nature Genetics, Cell, and Lancet. During the project period, the BBSR supported all 5 SJCCC Programs, resulting in 418 publications, which represent 20.2% of the total publications from the SJCCC during this period. The BBSR was used by 65 SJCCC members, 70% (n=46) of whom have cancer-relevant, peer-reviewed funding. In the next project period, the BBSR will actively evaluate new technology and analytical methods. New standard services and technology, such as Novaseq, will be introduced for SJCCC members. We will also continue to work with the SJCCC Programs to establish new molecular-profiling technology and to pursue bioinformatics method development in areas including network analysis; long-read technology (PacBio and Oxford Nanapore); single-cell RNA-Seq (DropSeq) and VDJ solution from 10X Genomics; and long-range chromatin-interaction assays (eg., Hi-C, HiChip, and Capture-C). Finally, we will continue deploying workflows to the newly established St. Jude Cloud platform, a Blue Sky initiative, to provide bench scientists within the SJCCC and around the world with direct access to sophisticated bioinformatics pipelines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-41
Application #
9883737
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Dove, Austin P; Manole, Bogdan-Alexandru; Wakefield, Daniel V et al. (2018) Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience. Pediatr Blood Cancer 65:e27408
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Chamdine, Omar; Elhawary, Ghada Ahmad Saad; Alfaar, Ahmad Samir et al. (2018) The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst 34:431-439
Heitzer, Andrew M; Ashford, Jason M; Harel, Brian T et al. (2018) Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma. J Neurooncol :
Robinson, Katherine M; Yang, Wenjian; Haidar, Cyrine E et al. (2018) Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics J :
Teitz, Tal; Fang, Jie; Goktug, Asli N et al. (2018) CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 215:1187-1203
Binder, Randall J; Hatfield, M Jason; Chi, Liying et al. (2018) Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors. Eur J Med Chem 149:79-89
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Donohoe, Clare; Bosi, Judy K; Sykes, April et al. (2018) Clinical Characteristics of Children and Adolescents Undergoing Hematopoietic Cell Transplantation Who Develop Oral Mucositis. Oncol Nurs Forum 45:457-462
Green, Daniel M; Wang, Mingjuan; Krasin, Matthew J et al. (2018) Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology :

Showing the most recent 10 out of 6764 publications